Investigational drug · Phase 3
Trontinemab
Also called: RO7126209, RG6102
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alzheimers Disease, Alzheimer's Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "Trontinemab"
First trial start
2021
Mar 15, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Trontinemab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimers Disease
- Alzheimer's Disease
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Trontinemab" as an intervention, largest first.
- A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07717411 · 1,600 participants (planned) · Start Oct 2, 2026 · Primary completion Jul 30, 2032
Drug: Trontinemab; Placebo · For: Alzheimer's Disease
Sites: Irvine, California; Long Beach, California; Los Angeles, California · 72 sites in all
- A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07169578 · 1,101 participants · Start Sep 17, 2025 · Primary completion Feb 16, 2028
Drug: Trontinemab · For: Alzheimers Disease
Sites: Birmingham, Alabama; Sun City, Arizona; Irvine, California · 142 sites in all
- A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07170150 · 1,060 participants · Start Nov 12, 2025 · Primary completion Feb 16, 2028
Drug: Trontinemab · For: Alzheimers Disease
Sites: Phoenix, Arizona; Imperial, California; Long Beach, California · 147 sites in all
- Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's DiseasePivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04639050 · 241 participants · Start Mar 15, 2021 · Primary completion Jul 31, 2027
Drug: RO7126209; Placebo · For: Alzheimers Disease
Sites: Atlantis, Florida; Clermont, Florida; Lady Lake, Florida · 37 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease.
Lozupone M, Dibello V, Sardone R, et al. · Expert Opin Emerg Drugs 2026
- Transport pathways across the blood-brain barrier for waste clearance and drug delivery.
Gröbner LS, Pietrzik CU · Fluids Barriers CNS 2026
- Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies.
Muliaditan M, van Steeg TJ, Avery LB, et al. · MAbs 2025
- [Anti-amyloid Antibody Drugs as Disease-Modifying Therapies for Alzheimer's Disease].
Sato K, Iwatsubo T · Brain Nerve 2024
- Delivery of the Brainshuttleࡊ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans.
Grimm HP, Schumacher V, Schäfer M, et al. · MAbs 2023
Also in development for Alzheimers Disease
- HT-4253Phase 21 trial
Halia Therapeutics, Inc. · Alzheimers Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.